OTC Markets OTCPK - Delayed Quote USD

Innate Pharma S.A. (IPHYF)

2.9000

0.0000

(0.00%)

At close: January 29 at 3:00:00 PM EST

Innate Pharma doses first patient in Nectin-4 ADC trial

The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal cells unharmed.

Clinical Trials Arena 3 days ago

IPH.PA
0.00%
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

MARSEILLE, France, January 27, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4.

Business Wire 4 days ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

MARSEILLE, France, January 21, 2025--Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York

Business Wire 10 days ago

IPHA
+2.87%
IPHYF
0.00%
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

MARSEILLE, France, January 16, 2025--Number of shares and voting rights of Innate Pharma as of December 31, 2024

Business Wire 15 days ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Announces Transformative Strategy to Accelerate Growth

MARSEILLE, France, January 10, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide.

Business Wire 21 days ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

MARSEILLE, France, December 20, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA.

Business Wire last month

IPHA
+2.87%
IPHYF
0.00%
3 Promising Penny Stocks With Market Caps Under US$300M

As global markets experience a mixed performance, with major U.S. indices reaching record highs while others face declines, investors continue to navigate through a complex economic landscape. Amidst this backdrop, penny stocks remain an intriguing option for those looking to explore smaller or less-established companies that may offer value and growth potential. Despite being considered an outdated term by some, penny stocks highlight opportunities in firms with strong financials and the...

Simply Wall St. last month

1244.HK

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma SA Reveals Promising Lacutamab Trial Results

Innate Pharma SA (FR:IPH) has released an update. Innate Pharma SA has unveiled promising data from its TELLOMAK Phase 2 study, highlighting the potential of lacutamab to improve the quality of life for patients with cutaneous T-cell lymphoma. The study shows significant alleviation of symptoms such as severe itching and skin infections, offering hope for those with limited treatment options. For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.

TipRanks last month

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

MARSEILLE, France, December 09, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

Business Wire last month

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

MARSEILLE, France & DIAMOND BAR, Calif., December 06, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL).

Business Wire last month

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

MARSEILLE, France, December 03, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET® asset, have been selected for the American Society of hematology (ASH) Annual Meeting.

Business Wire last month

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Releases Its 2025 Financial Calendar

MARSEILLE, France, November 20, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2025 financial calendar:

Business Wire 2 months ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

MARSEILLE, France, November 19, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate’s proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654).

Business Wire 2 months ago

IPHA
+2.87%
IPHYF
0.00%
Discover 3 Promising Penny Stocks With Over US$90M Market Cap

Global markets have been experiencing significant movements, with U.S. stocks rallying to record highs following a "red sweep" in the elections, which has raised expectations for growth and tax reforms. In this context of shifting economic policies and market optimism, investors are increasingly looking at under-the-radar opportunities that can offer potential growth without excessive risk. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies...

Simply Wall St. 2 months ago

CYB.MI

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

MARSEILLE, France, November 13, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced its business update and financial results for the first nine months of 2024.

Business Wire 2 months ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

MARSEILLE, France, November 08, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will be presented at the SITC Annual Meeting 2024.

Business Wire 2 months ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

MARSEILLE, France, November 07, 2024--Innate Pharma announces conference call and webcast for third quarter 2024 results and business updates

Business Wire 2 months ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Announces Its Participation in Upcoming Investor Conferences

MARSEILLE, France, October 29, 2024--Innate Pharma announces its participation in upcoming investor conferences

Business Wire 3 months ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

MARSEILLE, France, October 14, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company’s new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.

Business Wire 3 months ago

IPHA
+2.87%
IPHYF
0.00%
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

MARSEILLE, France, September 30, 2024--Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024

Business Wire 3 months ago

IPHA
+2.87%
IPHYF
0.00%

Performance Overview

Return	IPHYF	CAC 40
YTD	0.00%	+9.00%
1-Year	+2.11%	+3.83%
3-Year	-23.08%	+14.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innate Pharma S.A. (IPHYF)

Innate Pharma doses first patient in Nectin-4 ADC trial

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

3 Promising Penny Stocks With Market Caps Under US$300M

Innate Pharma SA Reveals Promising Lacutamab Trial Results

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Innate Pharma Releases Its 2025 Financial Calendar

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Discover 3 Promising Penny Stocks With Over US$90M Market Cap

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

Performance Overview